Myelin Basic Protein (68-82), guinea pigMyelin Basic Protein CAS# 98474-59-0 |
- Amyloid β-Peptide (10-20) (human)
Catalog No.:BCC1026
CAS No.:152286-31-2
- Amyloid β-Protein (1-15)
Catalog No.:BCC1003
CAS No.:183745-81-5
- Beta-Amyloid (1-11)
Catalog No.:BCC1002
CAS No.:190436-05-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 98474-59-0 | SDF | Download SDF |
| PubChem ID | 71464368 | Appearance | Powder |
| Formula | C71H113N23O28 | M.Wt | 1736.81 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | TYR-GLY-SER-LEU-PRO-GLN-LYS-SER-GLN-ARG-SER-GLN-ASP-GLU-ASN | ||
| Solubility | H2O Peptide Solubility and Storage Guidelines: 1. Calculate the length of the peptide. 2. Calculate the overall charge of the entire peptide according to the following table: 3. Recommended solution: | ||
| Sequence | H2N-Tyr-Gly-Ser-Leu-Pro-Gln-Lys-Ser-Gln-Arg-Ser-Gln-Asp-Glu-Asn-OH | ||
| SMILES | CC(C)CC(C(=O)N1CCCC1C(=O)NC(CCC(=O)N)C(=O)NC(CCCCN)C(=O)NC(CO)C(=O)NC(CCC(=O)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CO)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CC(=O)N)C(=O)O)NC(=O)C(CO)NC(=O)CNC(=O)C(CC2=CC=C(C=C2)O)N | ||
| Standard InChIKey | ROVJYNCPHLNVSO-OXKPGLRSSA-N | ||
| Standard InChI | InChI=1S/C71H113N23O28/c1-33(2)25-44(90-65(116)46(30-95)82-54(103)29-81-57(108)36(73)26-34-10-12-35(98)13-11-34)69(120)94-24-6-9-49(94)68(119)88-41(16-20-52(76)101)61(112)83-37(7-3-4-22-72)58(109)92-47(31-96)66(117)86-39(14-18-50(74)99)60(111)84-38(8-5-23-80-71(78)79)59(110)93-48(32-97)67(118)87-40(15-19-51(75)100)62(113)89-43(28-56(106)107)64(115)85-42(17-21-55(104)105)63(114)91-45(70(121)122)27-53(77)102/h10-13,33,36-49,95-98H,3-9,14-32,72-73H2,1-2H3,(H2,74,99)(H2,75,100)(H2,76,101)(H2,77,102)(H,81,108)(H,82,103)(H,83,112)(H,84,111)(H,85,115)(H,86,117)(H,87,118)(H,88,119)(H,89,113)(H,90,116)(H,91,114)(H,92,109)(H,93,110)(H,104,105)(H,106,107)(H,121,122)(H4,78,79,80)/t36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Myelin Basic Protein (68-82), guinea pig Dilution Calculator
Myelin Basic Protein (68-82), guinea pig Molarity Calculator
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Myelin Basic Protein (68-82), guinea pig,(C71H113N23O28) is a peptide with the sequence Tyr-Gly-Ser-Leu-Pro-Gln-Lys-Ser-Gln-Arg-Ser-Gln-Asp-Glu-Asn, MW= 1736.79. Myelin basic protein (MBP) is a protein believed to be important in the process of myelination of nerves in the nervous system. Knockout mice deficient in MBP showed decreased amounts of CNS myelination and have developed a progressive disorder characterized by tremors, seizures, and early death. MBP research has centered on its role in demyelinating diseases, in particular, multiple sclerosis (MS). Several studies have uncovered the role of antibodies against MBP in the pathogenesis of MS.] Some studies have linked a genetic predisposition to MS to the MBP gene, though a majority have not. Some recent work has shown that inoculating an animal with MBP to generate an immune response against it increases blood–brain barrier permeability.
Figure1 Formula of Myelin Basic Protein (68-82), guinea pig
Figure2 Structure of Myelin Basic Protein
Ref:
1. Sakamoto Y, Kitamura K, Yoshimura K, Nishijima T, Uyemura K (March 1987). "Complete amino acid sequence of POprotein in bovine peripheral nerve myelin". J. Biol. Chem. 262 (9): 4208–14.
2. Deber CM, Reynolds SJ (April 1991). "Central nervous system myelin: structure, function, and pathology". Clin. Biochem. 24 (2): 113–34.
3. Inouye H, Kirschner DA (January 1991). "Folding and function of the myelin proteins from primary sequence data". J. Neurosci. Res. 28 (1): 1–17.
4. Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, Dilitz E, Deisenhammer F, Reindl M (July 2003). "Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event". N. Engl. J. Med. 349 (2): 139–45.
- Metoprolol Succinate
Catalog No.:BCC6519
CAS No.:98418-47-4
- Finasteride
Catalog No.:BCC2491
CAS No.:98319-26-7
- Nodulisporic acid C2
Catalog No.:BCC8326
CAS No.:
- Boc-D-3-Pal-OH
Catalog No.:BCC2652
CAS No.:98266-33-2
- Boc-D-2-Pal-OH
Catalog No.:BCC2654
CAS No.:98266-32-1
- Isotanshinone II
Catalog No.:BCN3002
CAS No.:98249-39-9
- Hupehenine
Catalog No.:BCN2617
CAS No.:98243-57-3
- Eltoprazine
Catalog No.:BCC5421
CAS No.:98206-09-8
- Eltoprazine hydrochloride
Catalog No.:BCC5422
CAS No.:98224-03-4
- 5,2',6'-Trihydroxy-6,7,8-trimethoxyflavone
Catalog No.:BCN1293
CAS No.:98187-98-5
- Difloxacin HCl
Catalog No.:BCC3764
CAS No.:98106-17-3
- Ailanthone
Catalog No.:BCN4531
CAS No.:981-15-7
- Pseudoginsenoside RT1
Catalog No.:BCN2794
CAS No.:98474-74-9
- Pseudoginsenoside RT5
Catalog No.:BCN1076
CAS No.:98474-78-3
- Methyl 2-bromomethyl-3-nitrobenzoate
Catalog No.:BCC9035
CAS No.:98475-07-1
- 4-Chloro-6-iodoquinazoline
Catalog No.:BCC8703
CAS No.:98556-31-1
- Sominone
Catalog No.:BCN8006
CAS No.:98569-64-3
- Cryptanoside A
Catalog No.:BCN7481
CAS No.:98570-81-1
- Schisandrone
Catalog No.:BCN3316
CAS No.:98619-25-1
- (S)-(-)-Bay K 8644
Catalog No.:BCC7108
CAS No.:98625-26-4
- Sarmentocymarin
Catalog No.:BCN7489
CAS No.:98633-61-5
- Nitrocaramiphen hydrochloride
Catalog No.:BCC6655
CAS No.:98636-73-8
- Zedoarondiol
Catalog No.:BCN3560
CAS No.:98644-24-7
- Methyl ganoderate H
Catalog No.:BCN3258
CAS No.:98665-11-3
Early activation of CD4+ and CD8+ T lymphocytes by myelin basic protein in subjects with MS.[Pubmed:26526848]
J Transl Med. 2015 Nov 2;13:341.
BACKGROUND: Multiple sclerosis is the most common autoimmune disorder affecting the central nervous system. In this study, whole blood samples were analyzed for activation capacity and the activatability of CD4+ and CD8+ T-lymphocytes by human total myelin basic protein (MBP), human MBP 104-118 fragment, and guinea pig MBP 68-82 fragment. METHODS: Whole blood samples from healthy human subjects were compared with samples from patients with multiple sclerosis (MS). In particular, the expression of CD69, a surface marker of T-lymphocyte activity, was measured via flow cytometry before and after 14 h of incubation with human total MBP, MBP 104-118 fragment and/or guinea pig MBP 68-82 fragment. The results were compared between 15 patients with MS and 15 healthy subjects. RESULTS: In response to all three MBP forms, CD4+ and CD8+ T-lymphocytes from patients with MS demonstrated greater activatability than those from healthy subjects. These results indicate that in patients with MS, latent pre-activation to MBP epitopes results in an increased activation capacity of T-lymphocytes. CONCLUSION: This effect may occur because immunization against MBP (at least in a subset of patients) plays a pathophysiological role in MS pathogenesis. Alternatively, this result may represent a non-specific, bystander autoimmune phenomenon.
